John Bardis, CEO, MedAssets:

I think the supply side of the business has grown pretty well, we are actually up approximately 10 percent over the prior year on the top line. But because of our leverage and the way our infrastructure functions, it creates substantial mid-teens EBITDA (earnings before interest, tax, depreciation and amortization) growth rates for us. So I think that it's a remarkable performer, but I think at this time, given that where we were a year ago, we continue to be under the microscope, Lindsey, in terms of performance. In other words, as we continue to show consistency in our performance, I think analysts on The Street will get more confidence in our ability to deliver, and quite frankly, that's what they should be focused on, challenging our ability to deliver. I think we do that, we continue to deliver better shareholder returns.

Lindsey Bell:

Okay. Great. Thank you so much for your time today.

John Bardis, CEO, MedAssets:

You too, Lindsey.

If you liked this article you might like

New Lifetime High Reached By MedAssets (MDAS)

MedAssets (MDAS) Reaches New Lifetime High Today

MedAssets (MDAS) Stock Gains on Sale to Pamplona Capital Management

Today MedAssets (MDAS) Hits New Lifetime High

Analysts' Actions -- Apple, Disney, Hershey and More